The most commonly reported adverse effects were gastrointestinal nausea, vomiting, diarrhoea, and constipation consistent with the GLP-1 receptor agonist class and generally dose-dependent
With discontinuation rates a concern for companies, drug developers and practitioners are working together to help patients manage the worst of these side effects so they can stay on drug and benefit from the significant weight loss generated by the popular injectables
As noted previously, currently we do not have any large clinical trials for the treatment of HF or CKD in patients with or without T2D using GLP-1RA
Protein and magnesium deficiencies are also common
The form is important because incomplete or missing information can delay review, and submission does not guarantee approval
Clinical effectiveness Tirzepatide (Mounjaro) has shown superior results in clinical studies compared to semaglutide